<div id="readability-page-1"><p>In a report released yesterday, Faisal Khurshid from Jefferies maintained a Hold rating on Summit Therapeutics, with a price target of <span id="expert-recommendation-target">$17.00</span>. The company’s shares closed yesterday at $16.12.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Khurshid covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Syndax Pharmaceuticals, and Revolution Medicines. According to TipRanks, Khurshid has an average return of <span>69.1%</span> and a 62.77% success rate on recommended stocks. </p> <p>Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.42, which is a 94.97% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Hold rating on the stock with a $16.00 price target.</p></div>

SMMT

IBBQ

SBIO

LABU

<p>Summit Therapeutics (SMMT) received a Hold rating from analyst Faisal Khurshid of Jefferies, with a price target of $17.00, while shares closed at $16.12. Khurshid has a 69.1% average return and 62.77% success rate. The analyst consensus for Summit is Strong Buy, with a price target of $31.42, indicating a 94.97% upside. Piper Sandler also maintained a Hold rating with a $16.00 price target.</p>

Tip Ranks

Summit Therapeutics

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Jefferies Financial

Syndax Pharma

Revolution Medicines

Piper Sandler Cos

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst